We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

101 hedge funds and large institutions have $749M invested in Epizyme, Inc in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 27 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $2.27M | Put options by funds: $1.16M

48% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 27

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

3% less funds holding

Funds holding: 104101 (-3)

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

35% less capital invested

Capital invested by funds: $1.15B → $749M (-$402M)

Holders
101
Holders Change
-3
Holders Change %
-2.88%
% of All Funds
2.29%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
15
Increased
40
Reduced
27
Closed
17
Calls
$2.27M
Puts
$1.16M
Net Calls
+$1.11M
Net Calls Change
-$673K
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$104M +$132K +9,100 +0.1%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$94.5M -$38.3M -2,636,624 -26%
PAI
3
Palo Alto Investors
California
$86.1M +$6.72M +462,547 +7%
NMC
4
NEA Management Company
Maryland
$81.1M
Vanguard Group
5
Vanguard Group
Pennsylvania
$53.3M +$3.9M +268,253 +7%
BlackRock
6
BlackRock
New York
$49.8M +$8.43M +579,662 +17%
State Street
7
State Street
Massachusetts
$25.2M +$6.26M +430,841 +27%
RG
8
Redmile Group
California
$24.2M +$10.4M +715,689 +59%
Jennison Associates
9
Jennison Associates
New York
$23.5M +$114K +7,867 +0.4%
FCMI
10
Foresite Capital Management II
California
$19.6M +$218K +15,000 +1%
RSCM
11
Rock Springs Capital Management
Maryland
$16.6M -$363K -25,000 -2%
Norges Bank
12
Norges Bank
Norway
$13.6M -$1.45M -99,502 -8%
DM
13
Deerfield Management
New York
$12.7M +$4.49M +309,000 +44%
FCMI
14
Foresite Capital Management III
California
$12.5M +$2.16M +148,585 +17%
Millennium Management
15
Millennium Management
New York
$12.5M +$5.23M +359,547 +56%
Franklin Resources
16
Franklin Resources
California
$12.1M -$1.09M -74,900 -7%
VOYA Investment Management
17
VOYA Investment Management
Georgia
$7.57M -$28.5K -1,958 -0.3%
Northern Trust
18
Northern Trust
Illinois
$7.25M +$878K +60,420 +12%
Citadel Advisors
19
Citadel Advisors
Florida
$6.93M +$1.66M +114,240 +26%
PCM
20
Peregrine Capital Management
Minnesota
$6.28M +$7.27M +500,000 New
Lord, Abbett & Co
21
Lord, Abbett & Co
New Jersey
$6.01M -$2.19M -150,613 -24%
TCM
22
Tekla Capital Management
Massachusetts
$5.72M
Geode Capital Management
23
Geode Capital Management
Massachusetts
$5.64M -$305K -20,962 -4%
OIM
24
Oracle Investment Management
Connecticut
$4.55M -$94.6K -6,511 -2%
T. Rowe Price Associates
25
T. Rowe Price Associates
Maryland
$4.51M +$5.01M +344,800 +2,344%

EPZM Hedge Fund Activity: Q4 2017 in Review

101 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2017, worth a combined $749M — down 35% from $1.15B a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of EPZM and 15 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 40 added.

The largest buyer was Redmile Group, adding an estimated $10.4M. The largest seller was Fidelity Investments, cutting an estimated $38.3M.

  • 101 institutional investors held Epizyme, Inc (EPZM) as of Q4 2017, down from 104 in Q3 2017.
  • Funds reported $749M of Epizyme, Inc stock for Q4 2017, down 35% quarter-over-quarter.
  • 15 funds opened new Epizyme, Inc positions in Q4 2017 and 17 closed out, a net change of -2 holders.
  • The largest Epizyme, Inc buyer in Q4 2017 was Redmile Group, an estimated $10.4M added.
  • The largest Epizyme, Inc seller in Q4 2017 was Fidelity Investments, an estimated $38.3M sold.

Based on aggregated 13F filings for Q4 2017.